Conclusion The clinical pathway developed in urban hospital for patients with type 2 diabetic ketoacidosis may be a cost-effectiveness model for disease management.
结论2型糖尿病酮症酸中毒专科诊疗路径作为一个疾病管理模式具有一定的成本效益。
The medicines included in the WHO Model List of Essential Medicines are selected with regard to disease prevalence, evidence of safety and efficacy, and comparative cost-effectiveness.
对《世卫组织基本药物标准清单》上所列药物的选择考虑到了患病率、安全性和药效证据，以及相对成本效益。
In patients with stable CAD, however, the cost-effectiveness of high-dose statin therapy is highly sensitive to model assumptions about statin efficacy and cost.
然而，对于稳定性CAD病人来说，大剂量抑制素疗法的费用效益高度敏感于关于抑制素效益和费用的模型假定。
应用推荐